February 20, 2025
Biofidelity will present launch details for Enspyre®, a novel target enrichment technology with a broad spectrum of potential applications that allows for selective enrichment of specified variants prior to sequencing.
January 09, 2025
Biofidelity and CellCarta today announced a strategic partnership agreement to utilize Aspyre® Lung in global clinical trials.
December 16, 2024
Biofidelity is proud to have been selected as a grant recipient by the Green Business Impact Programme, a collaborative effort led by Cambridge City Council, South Cambridgeshire District Council, Huntingdonshire District Council, the Cambridgeshire and Peterborough Growth Hub and the Cambridgeshire & Peterborough Combined Authority and administered by Allia Impact, Ltd.
February 20, 2025 Clinical Lab Products
Biofidelity is launching Enspyre, a novel target enrichment technology that significantly enhances next-generation sequencing (NGS) efficiency by selectively removing background DNA, improving sensitivity, reducing costs, and enabling new clinical and research applications.
January 14, 2025 Genomeweb
Biofidelity is hoping to improve minimal residual disease (MRD) testing and cancer patient monitoring with the rollout of its Enspyre sample enrichment platform.
April 12, 2024 Genomeweb
Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.
